Overview: HLA-CW6 Typing TestIntroduction: The HLA-CW6 Typing Test detects HLA-CW6 antigen to assess psoriasis or transplant risk, causing skin issues or rejection. Following 2023 ASHI guidelines, it uses PCR for high specificity, supporting transplant screening. This test is critical for guiding transplant decisions, evaluating psoriasis risk, and improving outcomes in molecular pathology for patients with suspected psoriasis or undergoing transplantation.
Other Names: HLA-CW6 Assay, HLA-CW6 Antigen Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HLA typing began in the 1960s with transplant immunology. PCR-based HLA-CW6 typing improved in the 2000s, enhancing psoriasis and transplant assessment.
Purpose: Assesses HLA-CW6 for psoriasis or transplant compatibility, guides treatment or organ matching, and evaluates risk in patients with skin issues or transplant needs.
Test Parameters: 1. HLA-CW6 Antigen
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of psoriasis, transplants, or family history of HLA-related conditions.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document psoriasis, skin issues, transplants, or family history of HLA-related conditions. Include current medications and prior transplant history.
Consent: Written consent required, detailing the tests purpose, compatibility or psoriasis implications, and potential need for treatment or transplant planning.
Procedural Considerations: Uses PCR to detect HLA-CW6 antigen. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for psoriasis or transplant assessment.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.
Clinical Significance: Positive HLA-CW6 indicates psoriasis risk or transplant compatibility, guiding treatment or transplant decisions. Negative results may require alternative HLA typing.
Specialist Consultation: Consult a dermatologist or transplant immunologist for result interpretation and planning.
Additional Supporting Tests: Skin biopsy, HLA-B, or antibody screening to assess psoriasis or transplant compatibility.
Test Limitations: Limited to HLA-CW6; other HLA loci may need testing. Clinical correlation is needed for psoriasis diagnosis.
References: ASHI HLA Guidelines, 2023; Journal of Investigative Dermatology, Nair RP, 2022.
